Barry Sechos | Independent Chairman
Barry has served on the Board since 2012 and has over 20 years experience as a director, business executive and corporate lawyer with particular experience in investment and asset management. Barry is Executive Director of the Sherman Group (an early-stage investor in the Company) and sits on the Board of many Sherman Group companies and investee companies.
Leo Lee | Executive Director
Leo has served on the Board since December 2017 and was appointed CEO on 23 January 2019. Leo is a Senior executive with over 20 years of experience in Pharmaceutical innovation, commercialisation, regulatory and policy. He has worked in North America, Asia and has lived and worked in Japan the last 12 years. Leo was previously President of Allergan, Japan and former President of Merck Japan.
Professor Graham Vesey | Executive Director
Graham is a co-founder and founding CEO of Regeneus and has served on the Board since incorporation. Graham was appointed Chief Scientific Officer in November 2014. Graham is a successful biotechnology entrepreneur, technology innovator and inventor and a highly regarded scientist. Graham was a co-founder and Executive Director or the successful biotech start-up, BTF, which was sold to bioMerieux in 2007. Graham is an Adjunct Professor at Macquarie University.
Dr Alan Dunton | Non-Executive Director
Dr. Dunton joined the Board in April 2019. Dr Dunton is a senior pharmaceutical and biotechnology industry leader with over 35 years of experience in senior company leadership roles.
Dr Dunton has served as a director of 18 companies and is based in Florida, USA. He is the founder and principal of Danerius, LLC, a consultancy that provides specialised advisory services to pharmaceutical and biotechnology organisations both in the private and public sectors. Over the last few years, Dr Dunton has also served as an independent board director for a variety of publicly-listed biopharmaceutical and drug development companies such as Palatin Technologies, Oragenics and CorMedix and the private company, Cytogel Pharma.
Dr John Chiplin | Non-Executive Director
Dr Chiplin joined the Board in April 2019. Dr Chiplin is Managing Director of Newstar Ventures Ltd. and has significant operational, investment and transactions experience in the international life science and technology industries. Between 1995 and 2014, Dr Chiplin served as CEO at three leading publicly-listed software, biotechnology and cancer immunotherapy companies.
Based in London, UK, Dr Chiplin currently serves on the boards of Adalta (ASX:1AD), Batu Biologics, Scancell Holdings plc (LSE: SCLP, Chairman) and ScienceMedia.